Company registration number 11579884 (England and Wales)
MAGNITUDE BIOSCIENCES LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2026
PAGES FOR FILING WITH REGISTRAR
MAGNITUDE BIOSCIENCES LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 9
MAGNITUDE BIOSCIENCES LIMITED
BALANCE SHEET
AS AT
28 FEBRUARY 2026
28 February 2026
- 1 -
2026
2025
Notes
£
£
£
£
Fixed assets
Intangible assets
3
16,746
10,047
Tangible assets
4
29,502
34,663
46,248
44,710
Current assets
Debtors
5
171,438
177,585
Cash at bank and in hand
139,978
159,196
311,416
336,781
Creditors: amounts falling due within one year
6
(240,432)
(339,056)
Net current assets/(liabilities)
70,984
(2,275)
Total assets less current liabilities
117,232
42,435
Creditors: amounts falling due after more than one year
7
-
0
(250)
Net assets
117,232
42,185
Capital and reserves
Called up share capital
9
422
347
Share premium account
1,699,982
1,200,057
Capital redemption reserve
20
20
Profit and loss reserves
(1,583,192)
(1,158,239)
Total equity
117,232
42,185
MAGNITUDE BIOSCIENCES LIMITED
BALANCE SHEET (CONTINUED)
AS AT
28 FEBRUARY 2026
28 February 2026
- 2 -

For the financial year ended 28 February 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 10 June 2026 and are signed on its behalf by:
Dr F Saleem
Director
Company registration number 11579884 (England and Wales)
MAGNITUDE BIOSCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2026
- 3 -
1
Accounting policies
Company information

Magnitude Biosciences Limited is a private company limited by shares incorporated in England and Wales. The registered office is Netpark Plexus, Thomas Wright Way, Sedgefield, England, TS21 3FD.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention The principal accounting policies adopted are set out below.

1.2
Going concern

At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

 

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

1.4
Intangible fixed assets other than goodwill

Intangible assets are measured at cost less accumulated amortisation and accumulated impairment losses.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Patents & licences
10% straight line
Website and software
25% straight line
1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Laboratory equipment
12.5%/25% straight line
Office equipment
25% straight line
Computer equipment
25% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

MAGNITUDE BIOSCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 FEBRUARY 2026
1
Accounting policies
(Continued)
- 4 -
1.6
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.8
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.9
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

MAGNITUDE BIOSCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 FEBRUARY 2026
1
Accounting policies
(Continued)
- 5 -
Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.11
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.12
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

1.13
Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

 

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

1.14
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

MAGNITUDE BIOSCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 FEBRUARY 2026
- 6 -
2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2026
2025
Number
Number
Total
20
21
3
Intangible fixed assets
Patents & licences
Website and software
Total
£
£
£
Cost
At 1 March 2025
9,981
3,157
13,138
Additions
6,765
-
0
6,765
At 28 February 2026
16,746
3,157
19,903
Amortisation and impairment
At 1 March 2025
-
0
3,091
3,091
Amortisation charged for the year
-
0
66
66
At 28 February 2026
-
0
3,157
3,157
Carrying amount
At 28 February 2026
16,746
-
0
16,746
At 28 February 2025
9,981
66
10,047
MAGNITUDE BIOSCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 FEBRUARY 2026
- 7 -
4
Tangible fixed assets
Laboratory equipment
Office equipment
Computer equipment
Total
£
£
£
£
Cost
At 1 March 2025
94,956
4,447
31,132
130,535
Additions
10,123
-
0
-
0
10,123
Disposals
(3,154)
-
0
-
0
(3,154)
At 28 February 2026
101,925
4,447
31,132
137,504
Depreciation and impairment
At 1 March 2025
75,382
2,835
17,655
95,872
Depreciation charged in the year
7,674
814
6,732
15,220
Eliminated in respect of disposals
(3,090)
-
0
-
0
(3,090)
At 28 February 2026
79,966
3,649
24,387
108,002
Carrying amount
At 28 February 2026
21,959
798
6,745
29,502
At 28 February 2025
19,574
1,612
13,477
34,663
5
Debtors
2026
2025
Amounts falling due within one year:
£
£
Trade debtors
9,713
69,831
Corporation tax recoverable
-
0
6,117
Other debtors
161,725
101,637
171,438
177,585
6
Creditors: amounts falling due within one year
2026
2025
£
£
Bank loans
250
1,000
Trade creditors
16,995
65,352
Taxation and social security
48,582
60,209
Other creditors
174,605
212,495
240,432
339,056
MAGNITUDE BIOSCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 FEBRUARY 2026
- 8 -
7
Creditors: amounts falling due after more than one year
2026
2025
£
£
Bank loans
-
0
250
8
Share-based payment transactions

The company operates eight EMI option schemes and one non-EMI share option scheme, with participating employees holding options to acquire Ordinary 1p shares in the company. There were 68,312 options were granted during year ended 28 February 2026, with a year end total of 116,202 share options remaining outstanding that have been granted to date in respect of the above schemes.

 

The options can only be exercised once specific criteria are met, and are subject to the terms

stipulated in the EMI share option contract. The charge, so calculated has been assessed as immaterial and as such no charge has been recognised in the current period.

Number of share options
Weighted average exercise price
2026
2025
2026
2025
Number
Number
£
£
Outstanding at 1 March 2025
50,251
51,501
4.09
4.10
Granted
68,312
-
0
0.24
-
0
Forfeited
(2,361)
0
(1,250)
0
3.83
4.86
Outstanding at 28 February 2026
116,202
50,251
5.54
4.09
Exercisable at 28 February 2026
4,496
4,496
0.001
0.001

Of the options outstanding at 28 February 2026, 4,496 have an exercise price of £0.001 and 111,706 have an exercise price between £4.45 and £6.67.

 

During the period ended 28 February 2023, options to acquire 4,496 Ordinary 1p shares vested on their grant date. Within the options granted this year, 62,000 vest on achievement of performance conditions over 4 years. The remaining options vest over 1-5 years from the grant date (1-3 years from grant and 1-3 years from the 1st or 2nd anniversary of grant). These options will become exercisable on an exit event.

 

2,361 share options were cancelled and no options exercised during the year.

MAGNITUDE BIOSCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 FEBRUARY 2026
- 9 -
9
Called up share capital
2026
2025
2026
2025
Ordinary share capital
Number
Number
£
£
Issued and fully paid
A Ordinary shares of 0.1p each
323,135
248,135
323
248
Ordinary shares of 0.1p each
99,369
99,369
99
99
422,504
347,504
422
347

During the year 75,000 A ordinary shares of £0.001 each were issued at a premium of £6.66567 each.

10
Operating lease commitments
As lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2026
2025
£
£
Total commitments
53,560
82,680
2026-02-282025-03-01falsefalsefalse10 June 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityDr F SaleemDr C SaunterDr S WatermanDr D McFerran115798842025-03-012026-02-28115798842026-02-28115798842025-02-2811579884core:PatentsTrademarksLicencesConcessionsSimilar2026-02-2811579884core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2026-02-2811579884core:PatentsTrademarksLicencesConcessionsSimilar2025-02-2811579884core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2025-02-2811579884core:PlantMachinery2026-02-2811579884core:FurnitureFittings2026-02-2811579884core:ComputerEquipment2026-02-2811579884core:PlantMachinery2025-02-2811579884core:FurnitureFittings2025-02-2811579884core:ComputerEquipment2025-02-2811579884core:CurrentFinancialInstrumentscore:WithinOneYear2026-02-2811579884core:CurrentFinancialInstrumentscore:WithinOneYear2025-02-2811579884core:Non-currentFinancialInstrumentscore:AfterOneYear2026-02-2811579884core:Non-currentFinancialInstrumentscore:AfterOneYear2025-02-2811579884core:CurrentFinancialInstruments2026-02-2811579884core:CurrentFinancialInstruments2025-02-2811579884core:ShareCapital2026-02-2811579884core:ShareCapital2025-02-2811579884core:SharePremium2026-02-2811579884core:SharePremium2025-02-2811579884core:CapitalRedemptionReserve2026-02-2811579884core:CapitalRedemptionReserve2025-02-2811579884core:RetainedEarningsAccumulatedLosses2026-02-2811579884core:RetainedEarningsAccumulatedLosses2025-02-2811579884core:ShareCapitalOrdinaryShareClass12026-02-2811579884core:ShareCapitalOrdinaryShareClass12025-02-2811579884core:ShareCapitalOrdinaryShareClass22026-02-2811579884core:ShareCapitalOrdinaryShareClass22025-02-2811579884core:ShareCapitalOrdinaryShares2026-02-2811579884core:ShareCapitalOrdinaryShares2025-02-2811579884bus:Director12025-03-012026-02-2811579884core:IntangibleAssetsOtherThanGoodwill2025-03-012026-02-2811579884core:PatentsTrademarksLicencesConcessionsSimilar2025-03-012026-02-2811579884core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2025-03-012026-02-2811579884core:PlantMachinery2025-03-012026-02-2811579884core:FurnitureFittings2025-03-012026-02-2811579884core:ComputerEquipment2025-03-012026-02-28115798842024-03-012025-02-2811579884core:PatentsTrademarksLicencesConcessionsSimilar2025-02-2811579884core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2025-02-28115798842025-02-2811579884core:PatentsTrademarksLicencesConcessionsSimilarcore:ExternallyAcquiredIntangibleAssets2025-03-012026-02-2811579884core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwillcore:ExternallyAcquiredIntangibleAssets2025-03-012026-02-2811579884core:ExternallyAcquiredIntangibleAssets2025-03-012026-02-2811579884core:PlantMachinery2025-02-2811579884core:FurnitureFittings2025-02-2811579884core:ComputerEquipment2025-02-2811579884core:Non-currentFinancialInstruments2026-02-2811579884core:Non-currentFinancialInstruments2025-02-28115798842024-02-2911579884bus:OrdinaryShareClass12025-03-012026-02-2811579884bus:OrdinaryShareClass22025-03-012026-02-2811579884bus:OrdinaryShareClass12026-02-2811579884bus:OrdinaryShareClass12025-02-2811579884bus:OrdinaryShareClass22026-02-2811579884bus:OrdinaryShareClass22025-02-2811579884bus:AllOrdinaryShares2026-02-2811579884bus:AllOrdinaryShares2025-02-2811579884bus:PrivateLimitedCompanyLtd2025-03-012026-02-2811579884bus:SmallCompaniesRegimeForAccounts2025-03-012026-02-2811579884bus:FRS1022025-03-012026-02-2811579884bus:AuditExemptWithAccountantsReport2025-03-012026-02-2811579884bus:Director22025-03-012026-02-2811579884bus:Director32025-03-012026-02-2811579884bus:Director42025-03-012026-02-2811579884bus:FullAccounts2025-03-012026-02-28xbrli:purexbrli:sharesiso4217:GBP